Skip to main content
Midas Edge

DarioHealth Corp.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

DRIO$2.06-13.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Stockholders’ Equity

​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Preferred Stock · ​ · paid-in · ​ · Accumulated · ​ · stockholders’
​ · ​ ​ ​ · Number** · ​ · Amount · ​ · Number · ​ · Amount · ​ · capital · ​ · deficit · ​ · equity
Balance as of January 1, 20241,359,592​$3​18,959​$*) -​$407,502​$(349,361)​$58,144
​​​​​​​​​​​​​​​​​​​​
Exercise of options536​​*) -​—​​—​​*) -​​—​​*) -
Exercise of pre-funded warrant to common stock159,355​​*) -​—​​—​​2,225​​—​​2,225
Extinguishment of preferred stock in connection with preferred stock modification—​​—​—​​—​​(12,194)​​12,194​​—
Deemed dividend related to issuance of preferred stock—​​—​—​​—​​10,429​​(10,429)​​—
Conversion of preferred stock to common stock240,374​​*) -​(10,601)​​*) -​​—​​—​​*) -
Issuance of warrants to service providers​—​​—​—​​—​​2,704​​—​​2,704
Stock-based compensation​159,563​​*) -​—​​—​​13,092​​—​​13,092
Issuance of preferred stock, net of issuance cost—​​1​41,227​​*) -​​38,530​​—​​38,531
Modification of warrants​—​​—​—​​—​​70​​—​​70
Net loss—​​—​—​​—​​—​​(42,747)​​(42,747)
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 20241,919,420​$4​49,585​$*) -​$462,358​$(390,343)​$72,019
​​​​​​​​​​​​​​​​​​​​
Round-up of shares due to reverse share split effectuated on August 28, 202553,518​​*) -​—​​—​​—​​—​​—
Exercise of pre-funded warrant to common stock299,681​​*) -​—​​—​​2,821​​—​​2,821
Issuance of common stock and prefunded warrant, net of issuance cost​1,154,420​​*) -​—​​—​​17,374​​—​​17,374
Modification of preferred stock​—​​—​—​​​​​1,604​​(1,604)​​—
Deemed dividend related to issuance of preferred stock—​​—​—​​—​​18,417​​(18,417)​​—
Conversion of preferred stock to common stock and prefunded warrant2,826,861​​*) -​(56,385)​​*) -​​​​​—​​*) -
Stock-based compensation​652,048​​*) -​—​​—​​9,365​​—​​9,365
Issuance of preferred stock, net of issuance cost​—​​—​6,800​​*) -​​6,815​​—​​6,815
Issuance of warrants in connection with Callodine Loan Facility, net of issuance cost​—​​—​—​​—​​1,140​​—​​1,140
Modification of Avenue warrants—​​—​—​​—​​102​​—​​102
Net loss—​​—​—​​—​​—​​(41,714)​​(41,714)
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 20256,905,948​$4​—​$—​$519,996​$(452,078)​$67,922

*) Represents an amount lower than $1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.